We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go: Expired investment: £136,827
Family Traveller aims to help and encourage families to have amazing experiences together. In 2013, Family Traveller launched their multi-platform media business to provide a trusted guide for families to help solve the problems and de-stress the process of family travel.
days to go: Expired investment: £287,550
Nimbli is a London-based Fintech company which is promoting financial inclusion in East Africa by using innovative technology. It is currently working in strategic partnership with a Major African Bank to launch its mobile application in 1Q 2019. Through its mobile application, Nimbli will provide better financial services to small and medium enterprises (SMEs) and help in reducing the number of people who don’t have credit access to zero.  
days to go: Expired investment: £65,670
AgeWage is a pension scoring system that provides customized information to the customers. By bringing together your pension pots, AgeWage scores each of the pension pot out of 100 and tells you how well they have worked for you. The scoring system offers information that helps the customer make decisions on how to consolidate pots, reinvest their money and most importantly, how to get their money back. The company has signed an MoU with Royal London to enter into B2B arrangements. It was also chosen for the Direct Support Innovate programme with the FCA. AgeWage has been voted the best new idea in the BGL partnership awards(2018). With its proceeds, the company is planning to invest in digital development, marketing the application to the general public and other organizations. Also, it is trying to build out the infrastructure to support the development of the product with third parties such as Annuity Providers, IFAs, and Drawdown Providers.
days to go: Expired investment: £317,760
Lenderwize are a SEIS approved, UK based Crowdlending platform for Telcos. They seek to bridge the cash flow gap for telecom operators which sell to big operators and must pay their vendors upfront whilst waiting for their own clients to pay them. Lenderwize currently has a working platform with over £5,000,000 in requests from borrowers and over £9,000,000 from institutional investors.  
days to go: Expired investment: £78,076
Moody is a health-tracking application that connects users with customised health, food and fitness advice based on their moods, symptoms and cycles. It endeavours to become a sustainable force for good in women's health. The company argues that women control >80% of household health spend and are 80% more likely than men to use a digital health app. It aims to harness these trends and capitalise on the global remote health care market that is forecast to hit £40 billion by 2025. 'The Moody Month' app featured in publications like Vogue, Grazia and The Guardian. It has witnessed over 136,000 downloads since its Version 1 release in 2019. The app has compiled over 5 million moods to date. The company will use the investment to scale its business globally and reach 1 million subscribers within a four-year time frame.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £142,026
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph